Laboratory Products 55
Premium Table Range Combines Chemical Resistance and Durability Hygienic furniture specialist Teknomek has launched a premium table range using Trespa®
TopLab®
Base tops. The freestanding tables are the first on the market to
combine a 304-grade stainless steel base with Trespa TopLab surfaces. The antimicrobial properties of the tables, combined with excellent chemical resistance and durability, make them an ideal option for cleanrooms and laboratories.
Sue Springett, Commercial Manager at Teknomek, said: “The new range meets the needs of the most discerning customers; 304 grade stainless steel is naturally anti-microbial and Trespa TopLab’s High Pressure Laminate (HPL) offers exceptionally smooth and biologically clean surface properties. It’s a meeting of quality with quality.”
Trespa employs Electron Beam Curing on its Toplab surfaces, which results in a closed surface that limits micropores that can harbour bacteria. It offers a RA count rivalling electropolished stainless steel - but at a much more cost-effective price point.
The TopLab surfaces are scratch and impact resistant, and their dense molecular coating makes them almost impervious to temperature, UV radiation and humidity. They are robust enough to manage mechanical, thermal and chemical sterilisation processes, including the most aggressive cleaning products.
As well as being tough, the surfaces combine with Teknomek’s hygienic design, which makes the tables quick and easy to clean. This offers greater access beneath and around the unit thanks to an additional 300mm ground clearance. Customers can also opt for a diamond rear rail to remove potential dirt traps, or a Trespa TopLab Base undershelf.
Sue Springett commented: “Trespa tops are available with other (mild) stainless steel bases. However, our intelligent, hygienic thinking makes for a much more considered solution for the pharma sector as compliance is a core consideration. The coming together of Teknomek and Trespa fulfils a particular need within this market and we plan to grow the range over the next 12 months.”
More information online:
ilmt.co/PL/4Z9K 51114pr@reply-direct.com
New System for High Pressure Reaction Screening
Asynt has developed a novel high-pressure reactor array that integrates directly with their Integrity 10 Reaction Station, enabling scientists to undertake up to 10 independently pressurised reactions (up to 100 barg) in parallel.
The Integrity 10 Reaction Station is designed to carry out parallel reactions, each with independent temperature control between -30°C and +150°C, making it perfect for Design of Experiments (DoE) testing. In chemical development, DoE protocols have become a reference method to speed up reaction optimisation, since it allows the assessment of a large number of reaction parameters through a small number of experiments.
Integration of the new high-pressure reactor array module enables scientists to run a mix of reactions simultaneously, with each experiment conducted under different conditions. This extends the utility of the Integrity 10 reaction station, maximising efficiency and saving precious fume hood space. Manufactured as standard from durable 316 Stainless Steel, Asynt is also able to fabricate the system from exotic alloys such as Hastelloy or Inconel.
Using the Integrity 10 reaction station allows scientists to design automated reaction profiles for each individual experiment; with variations in temperature, pressure, stirring and time possible. All data is captured and recorded electronically and stored automatically.
More information online:
ilmt.co/PL/WErV 50913pr@reply-direct.com
Recombinant Antibodies for In Vivo Research Launched
Absolute Antibody Ltd has announced the launch of its VivopureX™ recombinant mouse antibodies for in vivoresearch in mouse models. The collection consists of popular antibody clones, many originally obtained from rats or hamsters, which Absolute Antibody has engineered into mouse-anti-mouse recombinant versions to improve research results. The antibodies are all available in discounted bulk sizes ranging from 1 mg to 100 mg.
VivopureX™ antibodies are species-matched chimeric antibodies, consisting of a clone’s original antigen-binding variable domain with a mouse constant domain, which means they do not induce neutralising antibodies in mouse models. As a result, the engineered recombinant antibodies offer many advantages compared to the original monoclonal antibodies, including increased long-term efficacy, stronger potency and a more consistent response across cohorts. In addition, VivopureX™ antibodies feature engineered effector functions, with Fc receptor binding tailored to best suit popular applications such as depletion, agonism or blocking.
All antibodies are produced recombinantly for ensured batch-to- batch reproducibility, and offer high purity and low endotoxin levels ideal for in vivo applications. The antibodies are targeted against key immune system proteins, including clinically relevant checkpoint proteins such as PD-1, CTLA-4 and OX40. Absolute Antibody data has shown that the recombinant mouse PD-1 antibody, based on the widely used clone RMP1-14, reduces tumour size in a mouse model more effectively than the original rat version.
51238pr@reply-direct.com
WWW.LABMATE-ONLINE.COM
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88
